About Immuneering
Immuneering (NASDAQ:IMRX) is a biotech firm dedicated to developing cutting-edge treatments aimed at addressing critical gaps in cancer and genetic disease therapies. At the core of their operations, they leverage advanced bioinformatics and computational biology to unearth novel insights that can lead to more effective medications. Their projects span various phases of drug development, from discovery through clinical trials, with a keen focus on leveraging their proprietary disease-canceling technology to engineer medications that offer improved efficacy and fewer side effects. The objective of Immuneering is to dramatically improve patient outcomes by bringing forward innovative therapies that can tackle diseases at their genetic roots, ultimately leading to healthier lives.
Snapshot
Operations
Products and/or services of Immuneering
- Development of precision oncology therapies targeting signaling pathways to inhibit tumor growth and progression.
- Bioinformatics services leveraging AI and machine learning to analyze genetic data for drug discovery.
- Proprietary disease cancellation technology aimed at identifying and nullifying disease signals in genomic data.
- Customized computational biology solutions that support pharmaceutical companies in drug development and discovery.
- Advanced analytics services that help in understanding the complex biology behind diseases for better treatment strategies.
- Development of a computational platform for identifying novel targets for cancer therapy through analysis of cancer cell signaling networks.
Immuneering executive team
- Dr. Benjamin J. Zeskind M.B.A., Ph.D.Co-Founder, President, CEO & Director
- Mr. Robert J. Carpenter M.B.A., M.S.Co-Founder & Chair Emeritus
- Dr. Brett M. Hall Ph.D.Chief Scientific Officer
- Mr. Michael D. Bookman J.D.Chief Legal Officer & Secretary
- Ms. Mallory Morales CPAPrincipal Financial & Accounting Officer, Chief Accounting Officer and Treasurer
- Ms. Paula George CPADirector of Accounting & Operations and Assistant Corporate Controller
- Ms. Leah R. NeufeldChief People Officer
- Dr. Peter King Ph.D.Head of Discovery & VP
- Dr. Praveen Nair Ph.D.Head of Translational Pharmacology & VP
- Mr. Harold E. BrakewoodChief Business Officer